Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII - PubMed (original) (raw)
. 1997 Sep 15;57(18):4130-40.
Affiliations
- PMID: 9307304
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
C J Wikstrand et al. Cancer Res. 1997.
Abstract
The potential of therapeutic targeting of tumor cell surface epidermal growth factor receptors (EGFRs) by modified ligands or specific antibodies has been limited by the normal tissue distribution of the receptor. The identification and characterization of a variant of this receptor, EGFRvIII, which is not expressed in normal tissues but has been described in gliomas, non-small cell lung carcinomas, and breast carcinomas, has provided a highly specific, internalizing target for antibody-mediated approaches. To determine the feasibility of immunotargeting EGFRvIII, we have assessed the qualitative distribution and quantitative expression at both the population and cellular levels of EGFRvIII in 21 biopsy samples of human gliomas by indirect analytical and quantitative flow cytometry and by immunohistochemical assay of frozen and formalin-fixed tissue. Consistent with previous reports, 50% of gliomas tested (1 of 2 anaplastic astrocytomas, 7 of 12 glioblastoma multiforme, and 2 of 6 oligodendrogliomas) expressed EGFRvIII, as determined by a minimum of 2 separate assays. Minimum estimates of the proportion of positive tumor cells in these populations ranged from 37-86%; in four of five cases in which quantitation of the EGFRvIII density/cell was performed, values of 2.7-6.8 x 10(5) were obtained with monoclonal antibody (mAb) L8A4 (EGFRvIII specific), levels consistent with successful in vivo immunotargeting. Confocal microscopic analysis confirmed that the subcellular localization of EGFRvIII was identical to that described for EGFR: predominant cell membrane expression, with some perinuclear distribution suggestive of localization to the Golgi region. Neither EGFR nor EGFRvIII was found within the nucleus. This study establishes for the first time that approximately 50% of human glioma biopsies contain cell populations expressing a sufficient number of membrane-expressed EGFRvIIIs to mediate specific anti-EGFRvIII mAb localization. Coupled with previous demonstrations of the rapid internalization of specific mAb-EGFRvIII complexes and the susceptibility of the targeted cells to isotope or toxin-mediated cytotoxicity, this study establishes the validity of targeting EGFRvIII for therapy of mutant receptor-positive gliomas, breast carcinomas, and non-small cell lung carcinomas.
Similar articles
- Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al. Wikstrand CJ, et al. Cancer Res. 1995 Jul 15;55(14):3140-8. Cancer Res. 1995. PMID: 7606735 - Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Tang CK, et al. Cancer Res. 2000 Jun 1;60(11):3081-7. Cancer Res. 2000. PMID: 10850460 - Tumor antigens in astrocytic gliomas.
Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Kurpad SN, et al. Glia. 1995 Nov;15(3):244-56. doi: 10.1002/glia.440150306. Glia. 1995. PMID: 8586461 Review. - The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. Wikstrand CJ, et al. J Neurovirol. 1998 Apr;4(2):148-58. doi: 10.3109/13550289809114515. J Neurovirol. 1998. PMID: 9584952 Review.
Cited by
- EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma.
Sterner RC, Sterner RM. Sterner RC, et al. Front Oncol. 2024 Sep 19;14:1434495. doi: 10.3389/fonc.2024.1434495. eCollection 2024. Front Oncol. 2024. PMID: 39364321 Free PMC article. Review. - Quantifying Imaging Agent Binding and Dissociation in 3-D Cancer Spheroid Tissue Culture Using Paired-Agent Principles.
Li C, Rounds CC, Torres VC, He Y, Xu X, Papavasiliou G, Samkoe KS, Brankov JG, Tichauer KM. Li C, et al. Ann Biomed Eng. 2024 Jun;52(6):1625-1637. doi: 10.1007/s10439-024-03476-2. Epub 2024 Feb 26. Ann Biomed Eng. 2024. PMID: 38409434 Free PMC article. - Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma.
Li F, Wu H, Du X, Sun Y, Rausseo BN, Talukder A, Katailiha A, Elzohary L, Wang Y, Wang Z, Lizée G. Li F, et al. Vaccines (Basel). 2023 Sep 5;11(9):1460. doi: 10.3390/vaccines11091460. Vaccines (Basel). 2023. PMID: 37766136 Free PMC article. Review. - Paclitaxel Delivery to the Brain for Glioblastoma Treatment.
AbdEl-Haq M, Kumar A, Ait Mohand FE, Kravchenko-Balasha N, Rottenberg Y, Domb AJ. AbdEl-Haq M, et al. Int J Mol Sci. 2023 Jul 21;24(14):11722. doi: 10.3390/ijms241411722. Int J Mol Sci. 2023. PMID: 37511480 Free PMC article. - Gene Targets of CAR-T Cell Therapy for Glioblastoma.
Wang C, Li Y, Gu L, Chen R, Zhu H, Zhang X, Zhang Y, Feng S, Qiu S, Jian Z, Xiong X. Wang C, et al. Cancers (Basel). 2023 Apr 18;15(8):2351. doi: 10.3390/cancers15082351. Cancers (Basel). 2023. PMID: 37190280 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous